60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
WASHINGTON, May 08, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that a letter, titled Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients, authored by the Company’s Chief Executive Officer, Geoff Dow, PhD, has been published in the Journal of Infectious Diseases. Dr. Dow’s letter responds to comments made on a recent article published in the Journal, “Tafenoquine-atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human babesiosis.” Those comments, by M Liu M, EM Galon EM, S Ji, and X Xuan, called for more published medical literature on safely and effectively treating babesiosis.